Israel Englander’s Adaptive Biotechnologies ADPT Stock Holding History

Israel Englander’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-100,000	Closed	-$671K	–	6060
2023 Q2	$671K	Sell	100,000 -70,000	-41%	-$520K	﹤0.01%	4337
2023 Q1	$1.5M	Buy	+170,000	New	+$1.5M	﹤0.01%	3712
2021 Q4	–	Sell	-10,000	Closed	-$340K	–	6706
2021 Q3	$340K	Buy	+10,000	New	+$362K	﹤0.01%	5722
2021 Q2	–	Sell	-10,000	Closed	-$403K	–	6455
2021 Q1	$403K	Buy	10,000 +5,000	+100%	+$271K	﹤0.01%	5002
2020 Q4	$296K	Buy	+5,000	New	+$258K	﹤0.01%	4555
2020 Q1	–	Sell	-20,000	Closed	-$598K	–	3782
2019 Q4	$598K	Buy	+20,000	New	+$574K	﹤0.01%	3275

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Israel Englander's ADPT Position: Q2 2026 in Review

Israel Englander reduced its Adaptive Biotechnologies (ADPT) stake by 53% in Q2 2026, selling an estimated $8.83M and leaving 504,909 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2205.

Israel Englander first reported a position in ADPT in Q2 2019 and has held it in 23 quarters since. The position peaked at $48.1M in Q3 2024. 298 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Israel Englander held 504,909 shares of Adaptive Biotechnologies worth $10.8M as of Q2 2026.
Israel Englander sold 576,457 Adaptive Biotechnologies shares in Q2 2026, an estimated $8.83M.
Adaptive Biotechnologies made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2205 holding.
Israel Englander first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 23 quarters since.
Israel Englander's Adaptive Biotechnologies position peaked at $48.1M in Q3 2024.
298 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.